Perjeta, Herceptin and gemcitabine – pro
A recent study substituted gemcitabine for docetaxel, although in the setting or previous treatment with docetaxel and progression on it and it suggests benefit.
At 3 months, 26/34 (76%) are progression free (1 CR, 8 PR, 17 SD); 8 pts progressed. There are no cardiac or febrile neutropenic events to date. 4 pts required G dose reduction (3 grade 3 neutropenia and 1 grade 3 vomiting) and the study was amended to lower initial G dose to 1000 mg/m2.
The information is too preliminary to based and this treatmetn remains E/I. This and similar clinical trials re ongoing.
Neil M. Iyengar, Lillian Mary Smyth, Diana Lake, Ayca Gucalp, Jasmeet Chadha Singh, Tiffany A. Traina, Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy. Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 1037-1037.